James Gow biography

James A. Gow M.D. serves as Senior Vice President - Clinical Development of the Company. Dr. Gow brings 20 years of leadership experience in clinical development and medical affairs at multinational ophthalmic companies. Prior to joining Aldeyra, from July 2019 to November 2019, Dr. Gow served as Vice President, Global Development Lead for lifitegrast (Xiidra®) on global clinical development projects at Novartis AG. Dr. Gow has also served in similar roles at Shire Pharmaceuticals Inc. from January 2018 to January 2019 and at Takeda Pharmaceutical Company Ltd. from January 2019 to June 2019 following Takeda’s acquisition of Shire in January 2019. During his career, Dr. Gow has held leadership positions of increasing responsibility at ISTA Pharmaceuticals, Inc. (acquired by Bausch and Lomb, Inc.), Bausch and Lomb, Inc. (acquired by Valeant Pharmaceuticals International, Inc., now Bausch Health Companies Inc.), Alcon Research, Ltd. from 2013 to 2016, and Inotek Pharmaceuticals Corporation (merged with Rocket Pharmaceuticals, Inc.) from 2016 to 2017. Dr. Gow received his B.Sc. major in zoology, B.Sc. (Med.), and M.D. from the University of Manitoba.